Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review

Schloss, Janet M., Colosimo, Maree, Airey, Caroline, Masci, Paul P., Linnane, Anthony W. and Vitetta, Luis (2013) Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review. Clinical Nutrition, 32 6: 888-893. doi:10.1016/j.clnu.2013.04.007


Author Schloss, Janet M.
Colosimo, Maree
Airey, Caroline
Masci, Paul P.
Linnane, Anthony W.
Vitetta, Luis
Title Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review
Journal name Clinical Nutrition   Check publisher's open access policy
ISSN 0261-5614
1532-1983
Publication date 2013-12-01
Year available 2013
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.clnu.2013.04.007
Volume 32
Issue 6
Start page 888
End page 893
Total pages 6
Place of publication Amsterdam, Netherlands
Publisher Elsevier
Collection year 2014
Language eng
Abstract Chemotherapy induced peripheral neuropathy [CIPN] is a common significant and debilitating side effect resulting from the administration of neurotoxic chemotherapeutic agents. These pharmaco-chemotherapeutics can include taxanes, vinca alkaloids and others. Moderate to severe CIPN significantly decreases the quality of life and physical abilities of cancer patients and current pharmacotherapy for CIPN e.g. Amifostine and antidepressants have had limited efficacy and may themselves induce adverse side effects. To determine the potential use of nutraceuticals i.e. vitamin E, acetyl-L-carnitine, glutamine, glutathione, vitamin B6, omega-3 fatty acids, magnesium, calcium, alpha lipoic acid and n-acetyl cysteine as adjuvants in cancer treatments a systematic literature review was conducted. Revised clinical studies comprised of randomized clinical trials that investigated the anti-CIPN effect of nutraceuticals as the adjuvant intervention in patients administered chemotherapy. Twenty-four studies were assessed on methodological quality and limitations identified. Studies were mixed in their recommendations for nutraceuticals. Currently no agent has shown solid beneficial evidence to be recommended for the treatment or prophylaxis of CIPN. The standard of care for CIPN includes dose reduction and/or discontinuation of chemotherapy treatment. The management of CIPN remains an important challenge and future studies are warranted before recommendations for the use of supplements can be made.
Keyword Chemotherapy induced peripheral neuropathy
CIPN
Nutraceuticals
Vitamins
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 24 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 31 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 16 May 2013, 21:32:08 EST by Dr Luis Vitetta on behalf of Medicine - Princess Alexandra Hospital